- Powered by pmidcalc.org -
Home/Search

Hematopoietic Cell Transplantation Specific Comorbidity Index (HCT-CI) Sorror et al. 2005 Hematopoietic Cell Transplantation Specific Comorbidity Index (HCT-CI)

Want to save & export your results? Check out our demos

+1 point

- Arrhythmia: Atrial fibrillation or flutter, sick sinus syndrome, or ventricular arrhythmias
- Cardiac: Coronary artery disease, congestive heart failure, myocardial infarction, or EF (ejection fraction) ≤50%
- Inflammatory bowel disease: Crohn disease or ulcerative colitis
- Diabetes: Requiring treatment with insulin or oral hypoglycemics but not diet alone
- Cerebrovascular disease: Transient ischemic attack or cerebrovascular accident
- Psychiatric disturbance: Depression or anxiety requiring psychiatric consult or treatment
- Mild hepatic: Chronic hepatitis, bilirubin>ULN (upper limit of normal) to 1.5xULN, or AST/ALT >ULN to 2.5xULN
- Obesity: Patients with a body mass index > 35 kg/m2
- Infection: Requiring continuation of antimicrobial treatment after day 0

0
+2 points

- Rheumatologic: SLE (systemic lupus erythmatosis), RA (rheumatoid arthritis), polymyositis, mixed CTD (connective tissue disease), or polymyalgia rheumatica
- Peptic ulcer: Requiring treatment
- Moderate/severe renal: Serum creatinine >2 mg/dL, on dialysis, or prior renal transplantation
- Moderate pulmonary: DLco and/or FEV1 66%-80% or dyspnea on slight activity

0
+3 points

- Prior solid tumor: Treated at any time point in the patient’s past history, excluding nonmelanoma skin cancer
- Heart valve disease: Except mitral valve prolapse
- Severe pulmonary: DLco and/or FEV1 ≤65% or dyspnea at rest or requiring oxygen
- Moderate/severe hepatic: Liver cirrhosis, bilirubin >1.5xULN, or AST/ALT >2.5xULN

0
0
0
0
0
0
0

2-year Non-relapse mortality (NRM) and survival in the validation set

NRM and Survival: 14%

NRM mortality: 14%
Overall survival: 71%

0

Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8):2912-9. PMID: 15994282 | PMC free article
top


up down